XTANT MEDICAL HOLDINGS INC (XTNT) Stock Overview
USA - NYSEARCA:XTNT - US98420P3082 - Common Stock
XTNT Key Statistics, Chart & Performance
The current stock price of XTNT is 0.638 USD. In the past month the price increased by 4.37%. In the past year, price decreased by -4.78%.
XTNT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.25 | 36.60B | ||
| COO | COOPER COS INC/THE | 16.64 | 13.30B | ||
| SOLV | SOLVENTUM CORP | 11.59 | 12.22B | ||
| ALGN | ALIGN TECHNOLOGY INC | 13.27 | 9.05B | ||
| BLCO | BAUSCH + LOMB CORP | 34.21 | 5.09B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 21.87 | 4.74B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.05 | 3.50B | ||
| ICUI | ICU MEDICAL INC | 15.73 | 2.92B | ||
| XRAY | DENTSPLY SIRONA INC | 7.23 | 2.47B | ||
| HAE | HAEMONETICS CORP/MASS | 10.25 | 2.30B | ||
| UFPT | UFP TECHNOLOGIES INC | 22.02 | 1.47B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.32B |
Related stock screener links
About XTNT
Company Profile
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.
Company Info
XTANT MEDICAL HOLDINGS INC
664 Cruiser Lane
Belgrade Montana MONTANA 59714 US
CEO: Sean E. Browne
Employees: 225
Phone: 14063880480
XTANT MEDICAL HOLDINGS INC / XTNT FAQ
What is the stock price of XTANT MEDICAL HOLDINGS INC today?
The current stock price of XTNT is 0.638 USD. The price increased by 1.71% in the last trading session.
What is the ticker symbol for XTANT MEDICAL HOLDINGS INC stock?
The exchange symbol of XTANT MEDICAL HOLDINGS INC is XTNT and it is listed on the NYSE Arca exchange.
On which exchange is XTNT stock listed?
XTNT stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for XTANT MEDICAL HOLDINGS INC stock?
8 analysts have analysed XTNT and the average price target is 1.79 USD. This implies a price increase of 179.78% is expected in the next year compared to the current price of 0.638. Check the XTANT MEDICAL HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XTANT MEDICAL HOLDINGS INC worth?
XTANT MEDICAL HOLDINGS INC (XTNT) has a market capitalization of 83.14M USD. This makes XTNT a Micro Cap stock.
How many employees does XTANT MEDICAL HOLDINGS INC have?
XTANT MEDICAL HOLDINGS INC (XTNT) currently has 225 employees.
What are the support and resistance levels for XTANT MEDICAL HOLDINGS INC (XTNT) stock?
XTANT MEDICAL HOLDINGS INC (XTNT) has a support level at 0.64 and a resistance level at 0.65. Check the full technical report for a detailed analysis of XTNT support and resistance levels.
Is XTANT MEDICAL HOLDINGS INC (XTNT) expected to grow?
The Revenue of XTANT MEDICAL HOLDINGS INC (XTNT) is expected to grow by 10.6% in the next year. Check the estimates tab for more information on the XTNT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XTANT MEDICAL HOLDINGS INC (XTNT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XTNT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XTNT, evaluating the profitability, health, valuation and growth aspects
- XTANT MEDICAL HOLDINGS INC (XTNT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XTANT MEDICAL HOLDINGS INC (XTNT) Sales and EPS estimates to see what analysts future expectations are.
- XTANT MEDICAL HOLDINGS INC (XTNT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XTANT MEDICAL HOLDINGS INC (XTNT) Insider and Institutional Ownership to learn about the owners and their transactions.
- XTANT MEDICAL HOLDINGS INC (XTNT) Stock Chart to make your own analysis
- XTANT MEDICAL HOLDINGS INC (XTNT) Latest news and press-releases to stay up to date.
Does XTANT MEDICAL HOLDINGS INC (XTNT) stock pay dividends?
XTNT does not pay a dividend.
When does XTANT MEDICAL HOLDINGS INC (XTNT) report earnings?
XTANT MEDICAL HOLDINGS INC (XTNT) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of XTANT MEDICAL HOLDINGS INC (XTNT)?
XTANT MEDICAL HOLDINGS INC (XTNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
What is the Short Interest ratio of XTANT MEDICAL HOLDINGS INC (XTNT) stock?
The outstanding short interest for XTANT MEDICAL HOLDINGS INC (XTNT) is 0.04% of its float. Check the ownership tab for more information on the XTNT short interest.
XTNT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to XTNT. When comparing the yearly performance of all stocks, XTNT is a bad performer in the overall market: 70.37% of all stocks are doing better.
XTNT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XTNT. XTNT may be in some trouble as it scores bad on both profitability and health.
XTNT Financial Highlights
Over the last trailing twelve months XTNT reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -100% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.51% | ||
| ROE | -27.33% | ||
| Debt/Equity | 0.51 |
XTNT Forecast & Estimates
8 analysts have analysed XTNT and the average price target is 1.79 USD. This implies a price increase of 179.78% is expected in the next year compared to the current price of 0.638.
For the next year, analysts expect an EPS growth of 83% and a revenue growth 10.6% for XTNT